Data Across 29 Presentations Highlights Precision, Accessibility and Platform-Agnostic Adoption, Establishing ALZpath’s Proprietary pTau217 as a Highly Accurate Industry Benchmark CARLSBAD, Calif., March 17, 2026 /PRNewswire/ — ALZpath, Inc., a leader in blood test-based diagnostic…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
